Hikari Power’s Ocular Therapeutix OCUL Stock Holding History

Hikari Power’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$167K	Hold	17,000	–	–	0.02%	42
2026 Q1	$144K	Hold	17,000	–	–	0.01%	50
2025 Q4	$206K	Hold	17,000	–	–	0.02%	62
2025 Q3	$199K	Hold	17,000	–	–	0.02%	62
2025 Q2	$158K	Hold	17,000	–	–	0.01%	62
2025 Q1	$125K	Hold	17,000	–	–	0.01%	59
2024 Q4	$145K	Hold	17,000	–	–	0.01%	58
2024 Q3	$148K	Hold	17,000	–	–	0.01%	61
2024 Q2	$116K	Hold	17,000	–	–	0.01%	60
2024 Q1	$155K	Hold	17,000	–	–	0.01%	61
2023 Q4	$76K	Hold	17,000	–	–	0.01%	63
2023 Q3	$53K	Hold	17,000	–	–	0.01%	64
2023 Q2	$88K	Hold	17,000	–	–	0.01%	63
2023 Q1	$90K	Hold	17,000	–	–	0.01%	64
2022 Q4	$48K	Hold	17,000	–	–	﹤0.01%	64
2022 Q3	$71K	Hold	17,000	–	–	0.01%	65
2022 Q2	$68K	Hold	17,000	–	–	0.01%	65
2022 Q1	$84K	Buy	17,000 +5,000	+42%	+$27.7K	0.01%	66
2021 Q4	$84K	Buy	+12,000	New	+$93.2K	0.01%	63
2018 Q4	–	Sell	-120,001	Closed	-$826K	–	129
2018 Q3	$826K	Buy	120,001 +39,990	+50%	+$251K	0.08%	72
2018 Q2	$540K	Hold	80,011	–	–	0.06%	75
2018 Q1	$521K	Hold	80,011	–	–	0.06%	71
2017 Q4	$356K	Buy	+80,011	New	+$409K	0.04%	71

Other funds holding OCUL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Hikari Power's OCUL Position: Q2 2026 in Review

Hikari Power held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 17,000 shares worth $167K. The position accounts for 0.02% of the portfolio, ranked #42.

Hikari Power first reported a position in OCUL in Q4 2017 and has held it in 23 quarters since. The position peaked at $826K in Q3 2018. 114 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Hikari Power held 17,000 shares of Ocular Therapeutix worth $167K as of Q2 2026.
Hikari Power left its Ocular Therapeutix share count unchanged in Q2 2026.
Ocular Therapeutix made up 0.02% of Hikari Power's portfolio in Q2 2026, its #42 holding.
Hikari Power first reported a position in Ocular Therapeutix in Q4 2017 and has held it in 23 quarters since.
Hikari Power's Ocular Therapeutix position peaked at $826K in Q3 2018.
114 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Hikari Power's 13F filing for Q2 2026, filed 7 Aug 2026.